FDA向阿斯利康瑞典南泰利耶工厂签发483检查观察报告(中英对照全文)
FDA 483:阿斯利康瑞典南泰利耶工厂(中英对照全文)
FDA在2026年4月7日至10日检查阿斯利康瑞典南泰利耶工厂后,签发Form FDA 483检查观察报告,列出2项观察。观察涉及偏差调查不充分、片剂中异物颗粒来源未能查明,以及CAPA系统未能确保实施防止再发生的措施。原文注明这些属于检查性观察,不代表FDA对合规性的最终判定。
2026年4月7日至10日,美国食品药品监督管理局(FDA)对阿斯利康公司(AstraZeneca AB,FEI 3003342394,地址:瑞典南泰利耶 Södertälje,Gärtunavägen,邮编151 85)的药品生产设施进行检查,签发 FDA 483 检查观察报告(Form FDA 483),列出 2 项观察,涉及偏差调查不充分、片剂中异物颗粒来源未查明、CAPA 系统不足等。如下:
FDA 483 检查观察报告(中英对照)
DEPARTMENT OF HEALTH AND HUMAN SERVICES
美国卫生与公众服务部
FOOD AND DRUG ADMINISTRATION
美国食品药品监督管理局(FDA)
DISTRICT ADDRESS AND PHONE NUMBER:12420 Parklawn Drive, Room 2032 Rockville, MD 20857
地区办公室地址及电话号码:马里兰州罗克维尔市 Parklawn Drive 12420 号 2032 室,邮编 20857
DATE(S) OF INSPECTION:04/07/2026-04/10/2026
检查日期:2026年4月7日 – 2026年4月10日
FEI NUMBER:3003342394
FEI 编号(企业识别号):3003342394
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED:Mr. Hans Fredrik Aasell, VP Sweden Operations
报告交付对象姓名及职务:Hans Fredrik Aasell 先生,瑞典运营副总裁
FIRM NAME:AstraZeneca AB
公司名称:阿斯利康(AstraZeneca AB)
STREET ADDRESS:Gartunavagen
街道地址:Gärtunavägen(表内写作 Gartunavagen)
CITY, STATE, ZIP CODE, COUNTRY:Sodertalje, 151 85 Sweden
城市、州、邮政编码、国家:瑞典南泰利耶(Södertälje),邮编151 85
TYPE ESTABLISHMENT INSPECTED:Drug Manufacturer
被检查机构类型:药品生产商
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.
本文件列出 FDA 代表在检查贵方设施期间提出的观察项。这些属于检查性观察,不代表 FDA 对贵方合规性的最终判定。如贵方对某项观察有异议,或已实施、计划实施针对某项观察的纠正措施,可在检查期间与 FDA 代表讨论该异议或措施,或将相关信息提交至上文地址的 FDA。如有任何疑问,请通过上文电话号码和地址联系 FDA。
DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:
在检查贵方工厂期间,我方观察到以下事项:
QUALITY
质量
OBSERVATION 1
观察项 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed. Specifically,
无论该批产品是否已经发运销售,公司均未能对任何无法解释的偏差进行彻底审查。具体如下:
Your firm's investigations of deviations are not always adequate.
贵公司对偏差的调查并非始终充分。
a. Quality Event QE-239020 was initiated 16NOV2025 following the identification of foreign particles in (b)(4) batches of (b)(4) tablets. Analytical characterization identified the particles as containing (b)(4). Your investigation proposed the potential source as excipient/API (b)(4) material). The following batches were affected:
a. 2025年11月16日,在(b)(4)批次(b)(4)片剂中发现异物颗粒后,启动了质量事件 QE-239020。分析表征鉴定这些颗粒含有(b)(4)。贵公司的调查提出其潜在来源为辅料/原料药(b)(4)物料)。受影响的批次如下:
Strength | Batch | Expiration Date | Quantity of (b)(4) tablets found with foreign | Quantity of (b)(4) Tablets Inspected | Quantity of Tablets manufactured
规格 | 批号 | 有效期至 | 检出异物的(b)(4)片剂数量 | 检查的(b)(4)片剂数量 | 生产的片剂数量
(b)(4)
(b)(4)(下表数据区域被整块涂黑)
Despite the inability to conclusively identify the source of the (b)(4) material, your investigation was closed. No additional investigation was conducted to definitively determine the origin of the (b)(4) material to prevent recurrence.
尽管无法最终确定(b)(4)物料的来源,贵公司的调查仍被关闭。未开展额外的调查以明确(b)(4)物料的来源,从而防止问题再次发生。
b. Quality Event QE-226480 was initiated 11SEP2025 during the manufacture (b)(4) mg tablets, Batch (b)(4) QTY: (b)(4) tablets, EXP: (b)(4) when four instances of (b)(4) (b)(4) were observed in (b)(4) 2, where tablets (b)(4) and exhibited (b)(4). An abnormal (b)(4) was first detected during sublot (b)(4). Subsequent sublots (b)(4) showed (b)(4) with (b)(4) variation and (b)(4) surfaces. Tablets with inadequate (b)(4) from these sublots were discarded (b)(4)
b. 质量事件 QE-226480 于 2025年9月11日启动。当时在生产(b)(4) mg 片剂、批号(b)(4)、数量:(b)(4)片、有效期至:(b)(4)期间,在(b)(4) 2 中观察到四例(b)(4)(b)(4),这些片剂(b)(4)并呈现(b)(4)。在子批(b)(4)期间首次检测到异常的(b)(4)。后续子批(b)(4)显示出(b)(4)具有(b)(4)差异和(b)(4)表面。来自这些子批的(b)(4)不足的片剂被废弃(b)(4)。
Affected sublots were identified through in-process observation and appearance inspection and were subsequently discarded. The root cause was determined to be equipment performance, as the (b)(4) in the (b)(4) was not (b)(4). The correction included cleaning the (b)(4) for each sub lot during the batch. Despite the (b)(4) four times, no corrective and preventive action (CAPA) was initiated, and the issue was deemed minor.
受影响的子批通过过程观察和外观检查被识别,并随后被废弃。根本原因被确定为设备性能问题,因为(b)(4)中的(b)(4)未(b)(4)。纠正措施包括在该批生产期间对每个子批清洗(b)(4)。尽管(b)(4)发生了四次,仍未启动纠正和预防措施(CAPA),且该问题被认定为轻微。
OBSERVATION 2
观察项 2
The responsibilities and procedures applicable to the quality control unit are not fully followed. Specifically,
适用于质量控制部门的职责和程序未得到完全遵循。具体如下:
Your firm's CAPA system is not always adequate to ensure deviations have appropriate measures implemented to prevent recurrence. During the manufacturing of (b)(4) mg tablets, Batch (b)(4), QTY: (b)(4) tablets, EXP: (b)(4), manufactured from (b)(4) through (b)(4), in-process appearance testing revealed four tablets containing foreign particulate matter. This was from the inspection of (b)(4) tablets.
贵公司的 CAPA 系统并非始终充分,无法确保针对偏差实施适当的措施以防止再次发生。在生产(b)(4) mg 片剂、批号(b)(4)、数量:(b)(4)片、有效期至:(b)(4),生产周期从(b)(4)至(b)(4)期间,过程外观检测发现四片含异物颗粒的片剂。这是在检查(b)(4)片片剂时发现的。
Laboratory analysis identified the contaminant as (b)(4). Quality Event QE-239020 was initiated 16NOV2025, and your investigation attributed the defect to a worn tablet press. However, the preventative maintenance program was not updated to address the equipment wear condition that caused this deviation.
实验室分析鉴定污染物为(b)(4)。质量事件 QE-239020 于 2025年11月16日启动,贵公司的调查将缺陷归因于压片机磨损。然而,预防性维护计划未作更新,以处理导致该偏差的设备磨损状况。
SEE REVERSE OF THIS PAGE
见本页背面
Rowena S. Nguyen, Investigator
检查员:Rowena S. Nguyen
Allison A. Aldridge, PhD, Consumer Safety Officer
消费者安全官:Allison A. Aldridge 博士
04/10/2026
2026年4月10日
来源:制药经理人 · mp.weixin.qq.com